

## Curriculum Vitae

Name: Mohammad Reza

Surname: Namazi

Date of Birth: Nov. 9, 1972

Place of Birth: Shiraz, Iran

Marital status: Married

### Education:

- |                     |   |
|---------------------|---|
| Oct 2007 - Apr 2008 | Postdoc Fellowship, Dermatology Department, Wake-Forest University, USA   |
| 2001-2005           | Dermatology Training, Tehran/Shiraz Medical Schools, Tehran/Shiraz Universities of Medical Sciences, Tehran/Shiraz, Iran (Receiving Specialist Qualification in Dermatology on Sep 2005)  |
| 1991-1998           | General Medical Training, Shiraz Medical School, Shiraz University of Medical Sciences (SUMS), Shiraz, Iran <ul style="list-style-type: none"><li>• Attaining the 12<sup>th</sup> score among 11500 Iranian medical doctors taking the Residency Entrance Examination in 2001</li></ul> |

### Medical Practice (as General Practitioner):

- |                         |  |
|-------------------------|--|
| Dec 1998 - Jul 2000     | Bavanat Health Network (affiliated with SUMS), Fars Province, Iran |
| March 2000 - March 2001 | Dastgheib Hospital (affiliated with SUMS), Shiraz, Iran            |

### Academic Activities:

- |                       |  |
|-----------------------|--|
| June 2012 - Present   | Director, Shiraz Skin Research Center    |
| Nov 2005 - Present    | Assistant Professor of Dermatology, SUMS |
| May 2003 - March 2004 | Editorial Assistant, Iran J Med Sci      |

March 2000 - Sep 2001

Health System Research Unit, SUMS

**Important Awards and Honors:**

- 1: SUMS Best Student Researcher Award for the years 2002-2005
- 2: Award of the 9<sup>th</sup> Rhazes Medical Science Research Festival (the most prestigious Iranian medical research award)
- 3: Young Researcher in Dermatology Award, granted by the Iranian Society of Dermatology
- 4: SUMS Best Resident Award
- 5: SUMS Best Thesis Award
- 6: High H-Index Award, granted by the Iranian Health Ministry.
- 7: Award of the 15<sup>th</sup> Rhazes Medical Science Research Festival (the most prestigious Iranian medical research award).
- 8: Imrich Sarkany Non-European Memorial Scholarship 2010
- 9: **Scholarship from Lindau Nobel Laureate Meeting for the 60th Interdisciplinary Meeting of Nobel Laureates in Lindau, Germany.**
- 10: SUMS Best Researcher Award for the years 2009-2011.
- 11: **Leading Scientist of the Islamic Countries** (Announced by COMSTECH, 2008)
- 12: **Leading Scientist of the Shiraz University of Medical Sciences**

### Presentations:

- 1: Namazi MR: Sexual problems: the prevalence and relationship with sociocultural factors in a group of neurotic patients. *The 11th International Congress of Geographic Medicine*. Oct. 31-Nov. 3, 1998, Shiraz, Iran.
- 2: Namazi MR: Thiabendazole: a safe, economical, and powerful weapon against pediculosis. *The 8th Pan Arab Dermatosciences Congress*. Oct. 26-29, 2002, Kingdom of Bahrain.
- 3: Handjani F, Namazi MR: The beneficial and detrimental effects of linoleic acid on autoimmune disorders. *The 2nd Scientific Conference for Medical Students in the GCC countries*. Jan. 25-28, 2004, Al-Ayn, UAE.
- 4: Namazi MR: Hypothesis: Overexpression or overactivation of PAR-2 might be involved in the evolution of basal cell carcinoma. *The 16th International Congress of Geographic Medicine*, 1-4 Dec., 2003, Shiraz, Iran.
- 5: Namazi MR: Treatment of pediculosis capitis with thiabendazole: a pilot study. *International Congress of Therapeutic Innovations in Dermatology and Dermatocosmetology*, 23-25 Oct, 2004, Bangkok, Thailand.
- 6: Namazi MR: Novel speculative additions to the antipsoriatic arsenal. *The 7th International Congress of Dermatology*, Sep. 29-Oct.2, 2004, Tehran, Iran.
- 7: Namazi MR: Clinical uses of nicotinamide in dermatology. *The 2nd Pharmalines International Dermatology Conference and Exhibition*. Apr 6-9, 2007, Antalya, Turkey
- 8: Namazi MR, Fallahzadeh K, Lashkari H, Kamali E: Elevation of serum prolactin levels in patients with pemphigus vulgaris. *The 10th International Congress of Dermatology*. May 20-23, 2009, Prague, Czech Republic.
- 9: Namazi MR: Using retinoids as cosmeceuticals. *The 3rd Pharmalines' International Dermatology Conference and Exhibition*. July 2-5, 2009, Famagusta, Cyprus.
- 10: Namazi MR: Marked elevation of serum MIF levels in patients with pemphigus vulgaris. *The 7th EADV Spring Symposium*. May 13-16, 2010, Cavtat, Croatia

### **Membership:**

Iranian Society of Dermatology  
Iran's National Elite Organization  
Editorial board, J Pak Assoc Dermatologists  
Editorial board, J Clin Exp Dermatol Res  
Editorial board, World J Dermatol  
Editorial board, J Lasers Med Sci

### **Reviewer for Refereed Journals:**

Am J Clin Dermatol  
Br Med J (Learning)  
Dermatol Online J  
Histol Histopathol  
Saudi Med J  
Iran J Med Sci  
Iran J Immunol  
Eur J Dermatol  
J Kerman Univ Med Sci (Persian)  
J Dermatolog Treat  
Clin Exp Dermatol  
Exp Dermatol  
Ann Saudi Med  
Mycoses

### **Editorship:**

Viewpoint Section Editor, J Dermatolog Treat (indexed in PubMed and Medline)

### **Language skills:**

Very good user of English.  
The mother tongue is Persian.

## Publications:

### **A) Book chapters and Books:**

- 1: Namazi MR, Yosipovitch G. Diabetes Mellitus. In: Dermatological Signs of Internal Disease, edited by Callen J, Jorizzo J, Bologna J, Piette W, Zane JJ. Elsevier Mosby Saunders, 4<sup>th</sup> edn, 2009.
- 2: Namazi MR. IELTS: A Must Read Guide to Success. Navid Shiraz Publications, 1<sup>st</sup> edn, 2011.
- 3: Namazi MR. Killing of Elites in Iran (Persian). Nameye Parsi Publications, 1<sup>st</sup> edn, 2012.

### **B) Papers:**

(The most important papers and papers published in the most important journals are underlined)

- 1: Feily A, Pazyar N, **Namazi MR**. Propranolol as a novel addition to anti-Kaposi sarcoma armamentarium: a hypothesis. *Skinmed*. 2011 Nov-Dec;9(6):391. PubMed PMID: 22256631.
- 2: Sharifian M, Sari-Aslani F, Hemmatinejad B, Fallahzadeh MK, Kasraee B, J Khoshandish M, Miri R, Mohammadi-Samani S, Jowkar F, **Namazi MR**. D-penicillamine, a potent melanogenesis inhibitor, lacks any depigmenting effect on black guinea pig skin: the first randomized, evaluator-blinded, vehicle-controlled, in vivo study. *Acta Dermatovenerol Alp Panonica Adriat*. 2011 Jun;20(2):51-3. PubMed PMID: 21993701.
- 3: Feily A, **Namazi MR**, Seifmanesh H. Generalized pustular psoriasis-like dermatophytosis due to *Trichophyton rubrum*. *Acta Dermatovenerol Croat*. 2011;19(3):209-11. PubMed PMID: 21933649.
- 4: Fallahzadeh MK, Sari-Aslani F, Khelat R, **Namazi MR**. An erythematous plaque with overlying alopecia on the scalp of a child. *Arch Dermatol*. 2011 Sep;147(9):1097-102.

PubMed PMID: 21931053.

5: Dastgheib L, Jowkar F, Abdollahee A, **Namazi MR**. Mesalazine as a new therapeutic option for chronic idiopathic urticaria. J Dermatolog Treat. 2011 Jul19. [Epub ahead of print] PubMed PMID: 21770811.

6: Feily A, **Namazi MR**. Silymarin as a potential novel addition to the limited anti-vitiligo weaponry: an untested hypothesis. Int J Clin Pharmacol Ther. 2011 Jul;49(7):467-8. PubMed PMID: 21726498.

7: Feily A, **Namazi MR**. Decrease of insulin growth factor-1 as a novel mechanism for anti-androgen effect of isotretinoin and its reported association with depression in some cases. J Drugs Dermatol. 2011 Jul;10(7):793-4. Review. PubMed PMID: 21720662.

8: **Namazi MR**, Feily A. Homocysteine may accelerate skin aging: a new chapter in the biology of skin senescence? J Am Acad Dermatol. 2011 Jun;64(6):1175-8. PubMed PMID: 21571175.

9: Feily A, **Namazi MR**. Glucose-6-phosphate-dehydrogenase deficiency may impart susceptibility to the development of AIDS. Arch Med Res. 2011 Jan;42(1):77. PubMed PMID: 21376267.

10: Fallahzadeh MK, Roozbeh J, Geramizadeh B, **Namazi MR**. Interleukin-2 serum levels are elevated in patients with uremic pruritus: a novel finding with practical implications. Nephrol Dial Transplant. 2011 Oct;26(10):3338-44. Epub2011 Mar 3. PubMed PMID: 21372257.

11: Emad M, Hayati F, Fallahzadeh MK, **Namazi MR**. Superior efficacy of oral fluconazole 400 mg daily versus oral fluconazole 200 mg daily in the treatment of cutaneous leishmania major infection: a randomized clinical trial. J Am Acad Dermatol. 2011 Mar;64(3):606-8. PubMed PMID: 21315963.

12: Mirfazaelian H, **Namazi MR**, Daneshbod Y. Mees' lines. Scientific World Journal.2011 Feb 3;11:267-8. PubMed PMID: 21298217.

13: **Namazi MR**, Fallahzadeh MK, Schwartz RA. Strategies for prevention of scars: what can we learn from fetal skin? Int J Dermatol. 2011 Jan;50(1):85-93 Review. PubMed PMID: 21039435.

14: Feily A, Pazyar N, Rafeie E, Khazanee A, **Namazi MR**. An unusually large squamous cell carcinoma mass arising from the lower lip. Acta Dermatovenerol Alp Panonica Adriat. 2010 Oct;19(3):43-4. PubMed PMID: 20976422.

15: Jowkar F, **Namazi MR**. Statins in dermatology. Int J Dermatol. 2010 Nov;49(11):1235-43 Review. PubMed PMID:20964647.

16: Ghanizadeh A, **Namazi MR**, Davami MH. G6PD Deficiency as a predisposing factor for attention deficit/hyperactivity disorder: a hypothesis. Arch Med Res. 2010 Jul;41(5):391. PubMed PMID: 20851299.

17: Ghanizadeh A, **Namazi MR**. A novel explanation for isotretinoin-induced psychiatric problems and its practical implication. Clin Exp Dermatol. 2011 Mar;36(2):205-6. PubMed PMID: 20659121.

18: Strowd LC, Taylor SL, Jorizzo JL, **Namazi MR**. Therapeutic ladder for pemphigus vulgaris: emphasis on achieving complete remission. J Am Acad Dermatol. 2011 Mar;64(3):490-4. Epub 2010 Jul 14. PubMed PMID: 20633956.

19: Feily A, Khalesi M, **Namazi MR**. Topical imidazole-calcineurin inhibitor combination as an economical and efficacious treatment for dermatologic diseases. Dermatitis. 2010 Jun;21(3):178. PubMed PMID: 20487667.

20: Feily A, **Namazi MR**. Vitamin A + D ointment is not an appropriate emollient for atopic dermatitis. *Dermatitis*. 2010 Jun;21(3):174-5. PubMed PMID: 20487665.

21: **Namazi MR**, Jowkar F. Can proton pump inhibitors accentuate skin aging? *Arch Med Res*. 2010 Feb;41(2):147-8. Epub 2010 Mar 29. PubMed PMID: 20470945.

22: Fallahzadeh MK, Lashkarizadeh H, Kamali-Sarvestani E, **Namazi MR**. Elevation of serum prolactin levels in patients with pemphigus vulgaris: a novel finding with practical implications. *J Am Acad Dermatol*. 2010 Jun;62(6):1071-2. PubMed PMID:20466186.

23: Fallahzadeh MK, Borhani Haghghi A, **Namazi MR**. Proton pump inhibitors: predisposers to Alzheimer disease? *J Clin Pharm Ther*. 2010 Apr;35(2):125-6. PubMed PMID: 20456731.

24: **Namazi MR**, Fallahzadeh MK. n-index: a novel and easily-calculable parameter for comparison of researchers working in different scientific fields. *Indian J Dermatol Venereol Leprol*. 2010 May-Jun;76(3):229-30. Review. PubMed PMID:20445291.

25: Bahmani M, Fallahzadeh MK, Jowkar F, Khalesi M, Bahri-Najafi R, **Namazi MR**. Can topical phenytoin augment the therapeutic efficacy of PUVA against vitiligo? A double-blind, randomized, bilateral-comparison, placebo-controlled study. *J Dermatolog Treat*. 2011 Apr;22(2):106-8. Epub 2010 May 5. PubMed PMID: 20443664.

26: Fallahzadeh MK, **Namazi MR**, Gupta RC. Taurine: a potential novel addition to the anti-systemic sclerosis weaponry. *Arch Med Res*. 2010 Jan;41(1):59-61. Epub2010 Jan 29. Review. PubMed PMID: 20430256.

27: Feily A, **Namazi MR**. Increasing HIV infectivity by Neisseria gonorrhoea: role of host antiapoptotic proteins in enhanced transmission. *AIDS*. 2010 May15;24(8):1237. PubMed PMID: 20421747.



28: **Namazi MR**, Dastgheib L, Mazandarani J, Jowkar F. Clofazimine, an antimycobacterial with potent in vitro and in vivo leishmanicidal activity, is ineffective against cutaneous *Leishmania major* infection in humans. *J Am Acad Dermatol*. 2010 May;62(5):890-2. PubMed PMID: 20398820.

29: Shahkar H, Fallahzadeh MK, **Namazi MR**. ABO blood groups and pemphigus vulgaris: no relationship. *Acta Dermatovenerol Alp Panonica Adriat*.2010;19(1):49-51. PubMed PMID: 20372776.

30: Feily A, **Namazi MR**. Why is graft-versus-host disease sometimes associated with leukoderma and fewer melanocytic naevi? *J Cosmet Dermatol*. 2010Mar;9(1):64-5. PubMed PMID: 20367675.

31: Fallahzadeh MK, Khalesi M, **Namazi MR**. Lipodermatosclerosis: a commonly misdiagnosed complication of chronic venous insufficiency. *Scientific World Journal*. 2010 Apr 1;10:576-7. PubMed PMID: 20364242.

32: Naseri M, Hadipour A, Sepaskhah M, **Namazi MR**. The remarkable beneficial effect of adding oral simvastatin to topical betamethasone for treatment of psoriasis: a double-blind, randomized, placebo-controlled study. *Niger J Med*.2010 Jan-Mar;19(1):58-61. PubMed PMID: 20232758.

33: **Namazi MR**, Feily A. Hyperhomocysteinemia: can't it account for retinoid-induced fracture proneness? *Indian J Dermatol Venereol Leprol*. 2010 Mar-Apr;76(2):186-7. PubMed PMID: 20228554.

34: **Namazi MR**. Potential utility of indomethacin in enhancing the leishmanicidal activity of glucantime. *East Mediterr Health J*. 2009 Nov-Dec;15(6):1624-5. PubMed PMID: 20218157.

- 35: **Namazi MR**. Hypothesis: does propranolol afford protection against atherosclerosis? Niger J Med. 2009 Jul-Sep;18(3):339. PubMed PMID: 20120660.
- 36: Feily A, **Namazi MR**. The potential utility of coumarin and horse chestnut extract for treatment of central serous chorioretiniopathy. Niger J Med. 2009Oct-Dec;18(4):434-5. PubMed PMID: 20120155.
- 37: Ghanizadeh A, **Namazi MR**. A possible research and clinical implication of association of homocysteine and glutamate levels in brain for management of aggression. Int J Dev Neurosci. 2010 Apr;28(2):125. Epub 2010 Jan 25. PubMed PMID: 20100561.
- 38: **Namazi MR**, Jorizzo JL, Fallahzadeh MK. Rubeosis faciei diabeticorum: a common, but often unnoticed, clinical manifestation of diabetes mellitus. Scientific World Journal. 2010 Jan 8;10:70-1. PubMed PMID: 20062952.
- 39: **Namazi MR**. Opinion article by Habibzadeh and Yadollahie. Arch Iran Med. 2010 Jan;13(1):81; author reply 81-2. PubMed PMID: 20039776.
- 40: Feily A, **Namazi MR**. The preventive effect of calcitriol on skin squamous cell carcinoma may be due to its effect on prostaglandin E2 metabolism and biologic activity. Acta Dermatovenerol Croat. 2009;17(4):331-2. PubMed PMID: 20021988.
- 41: Feily A, **Namazi MR**. Cissampelos sympodialis Eichl (Menispermaceae) leaf extract as a possible novel and safe treatment for psoriasis. Sao Paulo Med J. 2009 Jul;127(4):241-2. PubMed PMID: 20011931.
- 42: Feily A, **Namazi MR**, Pazyar N, Saboktakin M, Saboktakin M. Garlic extract as a novel addition to antikeloid armamentarium: an untested hypothesis. J Altern Complement Med. 2009 Nov;15(11):1153-4. PubMed PMID: 19922245.
- 43: Fallahzadeh MK, **Namazi MR**. Opioid-mediated immunosuppression as a novel

mechanism for the immunomodulatory effect of ultraviolet radiation. Indian J Dermatol Venereol Leprol. 2009 Nov-Dec;75(6):622-3. PubMed PMID: 19915254.

44: **Namazi MR**, Fallahzadeh MK. Wound myiasis in a patient with squamous cell carcinoma. Scientific World Journal. 2009 Nov 1;9:1192-3. PubMed PMID: 19882087.

45: Jowkar F, Jamshidzadeh A, Pakniyat S, **Namazi MR**. Efficacy of nitricoxide-liberating cream on pityriasis versicolor. J Dermatolog Treat. 2010 Mar;21(2):93-6. PubMed PMID: 19878037.

46: **Namazi MR**, Fallahzadeh MK, Shaghelani H, Kamali-Sarvestani E. Marked elevation of serum macrophage migration inhibitory factor levels in patients with pemphigus vulgaris. Int J Dermatol. 2010 Feb;49(2):146-8. Epub 2009 Oct 1. PubMed PMID: 19799642.

47: Fallahzadeh MK, Borhani Haghighi A, **Namazi MR**, Fallahzadeh MH. Beta-thalassemia trait as a protective factor against Alzheimer disease. Alzheimer Dis Assoc Disord. 2009 Jul-Sep;23(3):186-7. Review. PubMed PMID:19730169.

48: Fallahzadeh MK, **Namazi MR**. Taurine: a novel preventer of neurofibroma growth? J Altern Complement Med. 2009 Aug;15(8):817. PubMed PMID: 19678771.

49: Feily A, Yaghoobi R, **Namazi MR**. The potential utility of green tea extract as a novel treatment for cutaneous leishmaniasis. J Altern Complement Med. 2009 Aug;15(8):815-6. PubMed PMID: 19678770.

50: Feily A, **Namazi MR**, Saboktakin M, Mehri M, Lotfi J, Ayoobi A, Ghadakzadeh S, Karimian N. Self-inflicted non-healing genital ulcer: a rare form of factitious disorder. Acta Dermatovenerol Alp Panonica Adriat. 2009 Jun;18(2):83-5. PubMed PMID: 19588064.

51: **Namazi MR**. Can immunologic intercourse afford protection against renal transplant rejection? *Med Hypotheses*. 2009 Nov;73(5):859. Epub 2009 Jun 28. PubMed PMID: 19564080.

52: **Namazi MR**. Cytochrome-P450 enzymes and autoimmunity: expansion of the relationship and introduction of free radicals as the link. *J Autoimmune Dis*. 2009 Jun 25;6:4. PubMed PMID: 19555503; PubMed Central PMCID: PMC2708150.

53: **Namazi MR**, Feily A. Green tea extract: a novel addition to the antihirsutism armamentarium? *J Altern Complement Med*. 2009 Jul;15(7):700-1. PubMed PMID:19534609.

54: Feily A, **Namazi MR**. Which is the best anti-convulsant drug for the treatment of epilepsy in psoriatic or other Th1 mediated skin disease patients? *G Ital Dermatol Venereol*. 2009 Jun;144(3):330-1. PubMed PMID: 19528916.

55: **Namazi MR**. Tranilast: a novel preventor of neurofibroma growth? *J Cosmet Dermatol*. 2009 Jun;8(2):146. PubMed PMID: 19527340.

56: Fallahzadeh MK, **Namazi MR**, Vakili H, Soveid M. Statins as potential addition to anti-Graves' ophthalmopathy armamentarium. *J Coll Physicians Surg Pak*. 2009 Jun;19(6):397. PubMed PMID: 19486587.

57: **Namazi MR**. Why children with atopic dermatitis have fewer melanocytic nevi? *Niger J Med*. 2009 Jan-Mar;18(1):113. PubMed PMID: 19485163.

58: **Namazi MR**. A short critique aimed to be constructive to authors, referees, and editors. *J Plast Reconstr Aesthet Surg*. 2010 Feb;63(2):e234. Epub 2009 May22. PubMed PMID: 19464973.

59: Jowkar F, Fallahi A, **Namazi MR**. Is there any relation between serum insulin and insulin-like growth factor-I in non-diabetic patients with skin tag? J Eur Acad Dermatol Venereol. 2010 Jan;24(1):73-4. Epub 2009 May 3. PubMed PMID:19453787.

60: Feily A, **Namazi MR**, Saboktakin M, Daneshpajuh F, Mehri M, Lotfi J.L-carnitine: a potential treatment for hyper-IgE syndrome. G Ital Dermatol Venereol. 2009 Apr;144(2):214. PubMed PMID: 19357631.

61: Zarifkar A, Habibi H, **Namazi MR**, Hosseinasab SJ, Mosavat SH, Khatibi A, Habibi H. Administration of heparanase-III improves the survival and angiogenesis of rat skin autografts. G Ital Dermatol Venereol. 2009 Apr;144(2):195-8. PubMed PMID: 19357626.

62: **Namazi MR**, Chee Leok GO. Vitiligo and diet: a theoretical molecular approach with practical implications. Indian J Dermatol Venereol Leprol. 2009 Mar-Apr;75(2):116-8. Review. PubMed PMID: 19293496.

63: **Namazi MR**. The Th1-promoting effects of dehydroepiandrosterone can provide an explanation for the stronger Th1-immune response of women. Iran J Allergy Asthma Immunol. 2009 Mar;8(1):65-9. PubMed PMID: 19279363.

64: Sabayan B, **Namazi MR**, Mowla A, Moniri SA. Are patients with Darier and Haily-Haily diseases susceptible to Alzheimer's disease? A theory based on abnormal intraneuronal Ca<sup>2+</sup> homeostasis. J Alzheimers Dis. 2009;16(3):521-3. Review. PubMed PMID: 19276546.

65: **Namazi MR**, Fallahzadeh MK, Roozbeh J. Nicotinamide as a potential novel addition to the anti-uremic pruritus weaponry. Saudi J Kidney Dis Transpl. 2009 Mar;20(2):291-2. PubMed PMID: 19237824.

66: Feily A, **Namazi MR**. Aloe vera in dermatology: a brief review. *G Ital Dermatol Venereol*. 2009 Feb;144(1):85-91. Review. PubMed PMID: 19218914.

67: **Namazi MR**. Aggravation of psoriasis by antimalarials: a comment on the pathogenic mechanism. *Indian J Dermatol Venereol Leprol*. 2008 Nov-Dec;74(6):675-6. PubMed PMID: 19172012.

68: **Namazi MR**, Sharifian M. Hypothesis: can kojic acid prevent xanthelasma formation? *G Ital Dermatol Venereol*. 2008 Dec;143(6):425. PubMed PMID: 19169216.

69: **Namazi MR**. The potential negative impact of proton pump inhibitors on the immunopharmacologic effects of chloroquine and hydroxychloroquine. *Lupus*. 2009 Feb;18(2):104-5. PubMed PMID: 19151110.

70: **Namazi MR**, Sharifian M. The potential anti-xanthoma and anti-atherosclerotic effects of proton pump inhibitors. *J Clin Pharm Ther*. 2008 Dec;33(6):579-80. PubMed PMID: 19138234.

71: **Namazi MR**, Maghsoodi M. Association of angiokeratoma of the vulva with angioma serpiginosum. *J Drugs Dermatol*. 2008 Sep;7(9):882-3. PubMed PMID:19112804.

72: **Namazi MR**. A possible pivotal role for transglutaminase 2 in the pathophysiology of cutaneous amyloidosis. *Indian J Dermatol Venereol Leprol*. 2008 Sep-Oct;74(5):521-2. PubMed PMID: 19052432.

73: **Namazi MR**. The molecular mechanisms of down-regulation of expression and activity of inducible nitric oxide synthase in the psoriatic lesions. *Niger J Med*. 2008 Oct-Dec;17(4):465-6. PubMed PMID: 19048770.

- 74: Dastgheib L, Monabati A, Mohammadian A, Sari-Aslani F, Marzban S, **Namazi MR**. Proteinase-activated receptor-2 expression in basal and squamous cell carcinomas compared with normal skin. J Cutan Pathol. 2009 Mar;36(3):314-7. Epub 2008 Nov19. PubMed PMID: 19032384.
- 75: **Namazi MR**, Jorizzo JL. Ant-induced alopecia: a case report and literature review. Arch Dermatol. 2008 Nov;144(11):1526-7. Review. PubMed PMID: 19015437.
- 76: **Namazi MR**, Hinckley ML, Jorizzo JL. Multiple collections of soft bluish nodules on the body. Familial glomangiomas. Arch Dermatol. 2008 Oct;144(10):1383-8. PubMed PMID: 18936406.
- 77: Namian AM, Shahbaz S, Salmanpoor R, **Namazi MR**, Dehghani F, Kamali-Sarvestani E. Association of interferon-gamma and tumor necrosis factor alpha polymorphisms with susceptibility to vitiligo in Iranian patients. Arch Dermatol Res. 2009 Jan;301(1):21-5. Epub 2008 Sep 27. PubMed PMID: 18820938.
- 78: **Namazi MR**. Paul Langerhans: a tribute to an admirable life in science. Arch Dermatol. 2008 Sep;144(9):1109. PubMed PMID: 18794454.
- 79: Mowla A, **Namazi MR**. Could sertraline afford protection against atherosclerosis? A medical hypothesis. South Med J. 2008 Oct;101(10):1071-2. PubMed PMID: 18791517.
- 80: **Namazi MR**. Potent inhibition of cholesterol biosynthesis as a novel mechanism for chloroquine's induced pruritus. Niger J Med. 2008 Jul-Aug;17(3):366-7. PubMed PMID: 18788271.
- 81: **Namazi MR**. Nevus lipomatosus cutaneous superficialis of the groin arising in the fifth decade of life. J Drugs Dermatol. 2008 Aug;7(8):787-8. PubMed PMID:18720697.
- 82: **Namazi MR**. The potential utility of indomethacin in enhancing the pediculocidal

activity of permethrin, pyrethrins, and DDT. *Med Hypotheses*. 2008 Oct;71(4):607-8. Epub 2008 Jul 17. PubMed PMID: 18639385.

83: Jowkar F, **Namazi MR**, Bahmani M, Monabati A. Triggering of pityriasis lichenoides et varioliformis acuta by radiocontrast iodide. *J Dermatolog Treat*.2008;19(4):249-50. PubMed PMID: 18608711.

84: Maddison B, **Namazi MR**, Samuel LS, Sanchez J, Pichardo R, Stocks J, Maruziva D, Yosipovitch G. Unexpected diminished innervation of epidermis and dermoepidermal junction in lichen amyloidosis. *Br J Dermatol*. 2008Aug;159(2):403-6. Epub 2008 Jun 28. PubMed PMID: 18547301.

85: **Namazi MR**. Ultraviolet light exerts a major part of its therapeutic efficacy against vitiligo by production of prostaglandin E2. *Dermatology*. 2008;217(2):149. Epub 2008 Jun 4. PubMed PMID: 18523390.

86: **Namazi MR**. Ecchymosis-like hyperpigmented mycosis fungoides. *Ann Saudi Med*.2008 May-Jun;28(3):228-9. PubMed PMID: 18500183.

87: **Namazi MR**, Bahmani M. What's your diagnosis? A 12-year-old girl with slightly pruritic bilateral nonulcerated plaques on the malleoli. *Ann Saudi Med*. 2008 May-Jun;28(3):221-2. PubMed PMID: 18500177.

88: **Namazi MR**, Jorizzo JL. Dramatic verrucae confined to the lower lip. *Scientific World Journal*. 2008 May 1;8:507. PubMed PMID: 18454262.

89: **Namazi MR**, Jowkar F. A succinct review of the general and immunological pharmacologic effects of proton pump inhibitors. *J Clin Pharm Ther*. 2008 Jun;33(3):215-7. Review. PubMed PMID: 18452407.



90: **Namazi MR**. Potential utility of disulfiram against leishmaniasis. Indian J Med Res. 2008 Feb;127(2):193-4. PubMed PMID: 18403799.

91: **Namazi MR**. Hypothesis: the potential utility of topical eflornithine against cutaneous leishmaniasis. Indian J Dermatol Venereol Leprol. 2008 Mar-Apr;74(2):158-9. PubMed PMID: 18388383.

92: **Namazi MR**, Kerchner KR, Pichardo RO. Essential type II mixed cryoglobulinemia causing pyoderma gangrenosum-like ulcers. Scientific World Journal. 2008 Feb 25;8:228. PubMed PMID: 18335149.

93: **Namazi MR**. Which cyclic antidepressants are superior for the treatment of depressed psoriatic patients? A theoretical molecular approach. Dermatol Online J. 2008 Jan 15;14(1):23. PubMed PMID: 18319040.

94: **Namazi MR**. Eyelash heterochromia. Pediatr Dermatol. 2008 Jan-Feb;25(1):138. PubMed PMID: 18304184.

95: **Namazi MR**. The potential utility of acetaminophen in the treatment of cell-mediated autoimmune disorders. Med Hypotheses. 2008;70(6):1228-9. Epub 2008 Jan 30. PubMed PMID: 18249073.

96: **Namazi MR**. Proton pump inhibitors may trigger vitiligo by rendering melanocytes prone to apoptosis. Br J Dermatol. 2008 Apr;158(4):844-5. Epub 2008 Jan 17. PubMed PMID: 18205862.

97: **Namazi MR**. Nicotinamide in dermatology: a capsule summary. Int J Dermatol. 2007 Dec;46(12):1229-31. Review. PubMed PMID: 18173513.

98: **Namazi MR**. Can excessive washing really be regarded as the major cause of atopic dermatitis? Trends Immunol. 2008 Jan;29(1):2; author reply 3. Epub 2007 Nov 28.

PubMed PMID: 18054283.

99: **Namazi MR**. Decreasing the expression of LFA-1 and ICAM-1 as well as hindering their interaction as the major mechanism for statin-induced neutrophil dysfunction. *Ann Thorac Surg*. 2007 Dec;84(6):2137-8. PubMed PMID: 18036969.

100: **Namazi MR**. Co-administration of statins and griseofulvin to maximally inhibit cutaneous delayed-type hypersensitivity as well as leukocyte extravasation in chronic venous insufficiency. *J Coll Physicians Surg Pak*. 2007 Sep;17(9):580-1. PubMed PMID: 17903416.

101: **Namazi MR**. Neurogenic dysregulation, oxidative stress, autoimmunity, and melanocytorrhagy in vitiligo: can they be interconnected? *Pigment Cell Res*. 2007 Oct;20(5):360-3. PubMed PMID: 17850509.

102: **Namazi MR**. A possible role for human follicle mites in skin's defense against bacteria. *Indian J Dermatol Venereol Leprol*. 2007 Jul-Aug;73(4):270. PubMed PMID: 17675744.

103: **Namazi MR**. Heck's disease. *Ann Saudi Med*. 2007 May-Jun;27(3):222. PubMed PMID: 17568175.

104: **Namazi MR**. Practice pearl: a novel anesthetic solution for decreasing the blood loss at the recipient site of hair transplantation (Namazi Solution). *Aesthetic Plast Surg*. 2007 Jul-Aug;31(4):415. Epub 2007 Jun 11. PubMed PMID:17562097.

105: **Namazi MR**. Increase of intracellular methylglyoxal levels as a mode of action of retinoids against psoriasis. *Dermatol Online J*. 2007 May 1;13(2):30. PubMed PMID: 17498449.

106: **Namazi MR**. Oral sex may afford protection against pemphigoid gestationis. Med Hypotheses. 2007;69(6):1386-7. Epub 2007 Feb 26. PubMed PMID: 17321693.

107: **Namazi MR**. Extension of the "Hygiene Hypothesis" to the negative association between acne and atopy, hematological malignancies, and malignant melanoma. Med Hypotheses. 2007;69(4):960-1. Epub 2006 Oct 23. PubMed PMID: 17056188.

108: **Namazi MR**. UV light may induce hypertrichosis through production of PGE2. Med Hypotheses. 2007;68(4):917-8. Epub 2006 Oct 12. PubMed PMID: 17045759.

109: **Namazi MR**. Glucose-6-phosphate-dehydrogenase deficiency is a possible predisposer to Th2-dominant disorders. Med Hypotheses. 2007;68(3):720. Epub 2006 Oct 2. PubMed PMID: 17011722.

110: **Namazi MR**. Glucose-6-phosphate-dehydrogenase deficiency is a possible risk factor for the development of toxic epidermal necrolysis. Med Hypotheses. 2007;68(2):466-7. Epub 2006 Sep 29. PubMed PMID: 17011137.

111: **Namazi MR**. Increased mortality in toxic epidermal necrolysis with thalidomide: corroborating or exonerating the pathogenetic role of TNF-alpha? Br J Dermatol. 2006 Oct;155(4):842-3. PubMed PMID: 16965441.

112: **Namazi MR**. Two novel molecular mechanisms to account for the therapeutic efficacy of contact dermatitis against alopecia areata. Int Immunopharmacol. 2006 May;6(5):862. Epub 2006 Jan 6. PubMed PMID: 16546718.

113: **Namazi MR**, Handjani F. Lithium: a potential treatment for hyper-IgE syndrome. Med Hypotheses. 2006;66(5):1047. PubMed PMID: 16455207.

114: Salmanpour R, Shahkar H, **Namazi MR**, Rahman-Shenas MR. Epidemiology of pemphigus in south-western Iran: a 10-year retrospective study (1991-2000). Int J

Dermatol. 2006 Feb;45(2):103-5. PubMed PMID: 16445496.

115: **Namazi MR.** Zinc-levamisole combination: Powerful synergistic immunopotentialiation? Med Hypotheses. 2006;66(6):1253. Epub 2006 Jan 24. PubMed PMID: 16434148.

116: **Namazi MR,** Handjani F, Amirahmadi M. Increased oxidative activity from hydrogen peroxide may be the cause of the predisposition to cataracts among patients with atopic dermatitis. Med Hypotheses. 2006;66(4):863-4. Epub 2005 Dec13. PubMed PMID: 16356652.

117: **Namazi MR.** Phenytoin as a novel anti-vitiligo weapon. J Autoimmune Dis. 2005 Nov 22;2:11. PubMed PMID: 16303054; PubMed Central PMCID: PMC1308849.

118: **Namazi MR.** Possible molecular mechanisms to account for the involvement of tryptase in the pathogenesis of psoriasis. Autoimmunity. 2005 Sep;38(6):449-52.Review. PubMed PMID: 16278151.

119: **Namazi MR.** Potential clinical uses of cetirizine in dermatology. Med Hypotheses. 2006;66(3):672-4. Epub 2005 Oct 25. PubMed PMID: 16253433.

120: **Namazi MR.** Treatment of acne could lead to the better control of cellular autoimmune disorders. Med Hypotheses. 2006;66(2):446-7. Epub 2005 Oct 25. PubMed PMID: 16253429.

121: **Namazi MR,** Handjani F, Sodaifi M. The potential utility of statins as novel weapons against graft-versus-host disease. Med Hypotheses. 2005;65(6):1203-4.Epub 2005 Sep 1. PubMed PMID: 16139438.

122: **Namazi MR.** The addition of tretinoin to permethrin, pyrethrins, and DDT for production of powerful anti-lice agents. Med Hypotheses. 2005;65(5):992. PubMed

PMID: 16040199.

123: **Namazi MR**, Tanideh N. In contrast with PAR-2 mediated nociception and hyperalgesia, melanosome transfer does not involve N-methyl-D-aspartate receptors. *J Drugs Dermatol*. 2005 May-Jun;4(3):278-9. PubMed PMID: 15898281.

124: **Namazi MR**. Cannabinoids, loratadine and allopurinol as novel additions to the antipsoriatic ammunition. *J Eur Acad Dermatol Venereol*. 2005 May;19(3):319-22. Review. Erratum in: *J Eur Acad Dermatol Venereol*. 2005 Jul;19(4):529. PubMed PMID: 15857457.

125: **Namazi MR**. The potential utility of sodium valproate as a novel addition to anti-multiple myeloma armamentarium. *Med Hypotheses*. 2005;64(6):1246-7. PubMed PMID: 15823734.

126: **Namazi MR**, Soma J. Tranilast: a novel weapon against insulin resistance. *Med Hypotheses*. 2005;64(6):1135-7. PubMed PMID: 15823702.

127: **Namazi MR**. Statins: novel weapons against granulomatous disorders and HIV infection? *Acta Dermatovenerol Alp Panonica Adriat*. 2004 Dec;13(4):137. PubMed PMID: 15818450.

128: Azizzadeh M, **Namazi MR**, Dastghaib L, Sari-Aslani F. Angiolymphoid hyperplasia with eosinophilia and nephrotic syndrome. *Int J Dermatol*. 2005 Mar;44(3):242-4. Review. PubMed PMID: 15807737.

129: **Namazi MR**. A novel molecular mechanism to account for the hygiene hypothesis. *Mol Immunol*. 2005 Apr;42(6):741. Epub 2004 Nov 23. PubMed PMID:15781118.

130: **Namazi MR**. Griseofulvin: a potential addition to anti-Crohn's disease armamentarium. *Scand J Gastroenterol*. 2005 Feb;40(2):244-5. PubMed

PMID:15764160.

131: **Namazi MR**. Steroid sulfatase inhibitors as novel additions to the antipsoriatic armamentarium. Med Sci Monit. 2005 Mar;11(3):HY7-9. PubMed PMID:15735572.

132: **Namazi MR**. Griseofulvin: a novel addition to anti-multiple sclerosis ammunition? Mult Scler. 2005 Feb;11(1):92. PubMed PMID: 15732274.

133: **Namazi MR**. The potential utility of statin vaginal gels in the prevention of HIV transmission. J Drugs Dermatol. 2005 Jan-Feb;4(1):16. PubMed PMID: 15696980.

134: Roozitalab MH, Amirahmadi M, **Namazi MR**. Results of the application of intraoperative mitomycin C in dacryocystorhinostomy. Eur J Ophthalmol. 2004 Nov-Dec;14(6):461-3. PubMed PMID: 15638092.

135: **Namazi MR**. Hypothesis: patients with dermatitis herpetiformis may be predisposed to depression and aggression. J Drugs Dermatol. 2004 Nov-Dec;3(6):601-2. PubMed PMID: 15624741.

136: **Namazi MR**. The beneficial effect of beta2-blockers on humoral autoimmune disorders. J Hypertens. 2004 Dec;22(12):2397-8. PubMed PMID: 15614035.

137: **Namazi MR**. Practice pearl: gargling with cholinergic ophthalmic drops for treating the oral lesions of pemphigus vulgaris. J Drugs Dermatol. 2004 Sep-Oct;3(5):484-5. PubMed PMID: 15552600.

138: **Namazi MR**. Further insight into the pathomechanism of acne by considering the 5-alpha-reductase inhibitory effect of linoleic acid. Int J Dermatol. 2004 Sep;43(9):701. PubMed PMID: 15357760.

139: **Namazi MR**. Prescribing antidepressant drugs for pemphigus patients: An

important point to keep in mind. *Dermatol Online J.* 2004 Jul 15;10(1):22. PubMed PMID: 15347504.

140: **Namazi MR.** Lichen planus pigmentosus presenting as diffuse facial melanosis. *J Drugs Dermatol.* 2004 Jul-Aug;3(4):436-7. PubMed PMID: 15303789.

141: **Namazi MR.** Imiquimod: a potential weapon against morphea and fibromatoses. *J Drugs Dermatol.* 2004 Jul-Aug;3(4):362-3. PubMed PMID: 15303778.

142: **Namazi MR.** Statins: novel additions to the dermatologic arsenal? *Exp Dermatol.* 2004 Jun;13(6):337-9. Review. PubMed PMID: 15186318.

143: **Namazi MR.** Nicotinamide as a potential addition to the anti-atopic dermatitis armamentarium. *Int Immunopharmacol.* 2004 Jun;4(6):709-12. Review. PubMed PMID: 15135312.

144: **Namazi MR.** Why is psoriasis uncommon in Africans? The influence of dietary factors on the expression of psoriasis. *Int J Dermatol.* 2004 May;43(5):391-2. PubMed PMID: 15117377.

145: **Namazi MR.** The beneficial and detrimental effects of linoleic acid on autoimmune disorders. *Autoimmunity.* 2004 Feb;37(1):73-5. PubMed PMID: 15115315.

146: **Namazi MR.** Paradoxical exacerbation of psoriasis in AIDS: proposed explanations including the potential roles of substance P and gram-negative bacteria. *Autoimmunity.* 2004 Feb;37(1):67-71. Review. PubMed PMID: 15115314.

147: **Namazi MR,** Handjani F. An immunologic mechanism for the therapeutic efficacy of minoxidil in alopecia areata. *J Drugs Dermatol.* 2004 Mar-Apr;3(2):129-30. PubMed PMID: 15098965.

148: **Namazi MR.** Nicotinamide: a potential anti-addiction weapon. *Med Hypotheses*.2004;62(5):844-5. PubMed PMID: 15082118.

149: **Namazi MR.** The cellular immunodeficiency associated with post-traumatic stress disorder may be the result of sympathetic overactivity and be correctable by beta-2-blockers. *Neuro Endocrinol Lett*. 2003 Dec;24(6):468. PubMed PMID:15073578.

150: **Namazi MR.** Cetirizine and allopurinol as novel weapons against cellular autoimmune disorders. *Int Immunopharmacol*. 2004 Mar;4(3):349-53. Review. PubMed PMID: 15037212.

151: **Namazi MR,** Mowla A. Massive right-sided hemorrhagic pleural effusion due to pancreatitis; a case report. *BMC Pulm Med*. 2004 Feb 17;4:1. PubMed PMID: 15018626; PubMed Central PMCID: PMC362879.

152: **Namazi MR.** The addition of diuretics to corticosteroids with high mineralocorticoid activity may lead to the better control of humoral autoimmune disorders. *Int Immunopharmacol*. 2004 Feb;4(2):325. PubMed PMID: 14996424.

153: **Namazi MR.** Hypothesis: overexpression or overactivation of PAR-2 might be involved in the evolution of basal cell carcinoma. *Dermatol Online J*. 2003 Dec;9(5):32. PubMed PMID: 14996405.

154: **Namazi MR.** Prostaglandin analogs for hair growth: greater expectations. *Dermatol Online J*. 2003 Dec;9(5):29. PubMed PMID: 14996402.

155: **Namazi MR.** Possible molecular mechanisms to account for the efficacy of allopurinol against experimental autoimmune uveitis. *Int Immunopharmacol*. 2004 Jan;4(1):161-2. PubMed PMID: 14975372.

156: **Namazi MR.** Diphenhydramine gargling may slow the healing of oral lesions of



pemphigus vulgaris. J Drugs Dermatol. 2004 Jan-Feb;3(1):12. PubMed PMID:14964741.

157: **Namazi MR**. Hypothesis: Superoxide scavengers or superoxide dismutase may potentiate the therapeutic efficacy of contact dermatitis against alopecia areata. J Drugs Dermatol. 2003 Dec;2(6):616. PubMed PMID: 14711134.

158: **Namazi MR**. Pyridoxal 5'-phosphate as a novel weapon against autoimmunity and transplant rejection. FASEB J. 2003 Dec;17(15):2184-6. PubMed PMID: 14656979.

159: **Namazi MR**. Treatment of pediculosis capitis with thiabendazole: a pilot study. Int J Dermatol. 2003 Dec;42(12):973-6. PubMed PMID: 14636196.

160: **Namazi MR**. Explaining decreased nitric oxide production in psoriatic lesions: arginase 1 overexpression versus calcitonin gene-related peptide. Am J Pathol. 2003 Dec;163(6):2642; author reply 2642-3. PubMed PMID: 14633638; PubMed Central PMCID: PMC1892353.

161: **Namazi MR**. Prescribing cyclic antidepressants for vitiligo patients: which agents are superior, which are not? Psychother Psychosom. 2003 Nov-Dec;72(6):361-2. PubMed PMID: 14526142.

162: **Namazi MR**, Handjani F. Angioma serpiginosum. Dermatol Online J. 2003 Aug;9(3):19. PubMed PMID: 12952766.

163: Naseri M, **Namazi MR**. Isolated scalp involvement with pityriasis versicolor alba (pityriasis versicolor albus capitis) in a patient from a dry, temperate region. Dermatol Online J. 2003 Aug;9(3):17. PubMed PMID: 12952764.

164: **Namazi MR**. Nicotinamide: a potential addition to the anti-psoriatic weaponry. FASEB J. 2003 Aug;17(11):1377-9. Review. PubMed PMID: 12890690.

165: **Namazi MR**. Nitric oxide donors as potential additions to anti-alopecia areata armamentarium. *Inflamm Res*. 2003 Jun;52(6):227-9. Review. PubMed PMID:12877147.

166: **Namazi MR**. Hypothesis: paradoxical absence of cellular immuno-deficiency in X-linked recessive ichthyosis and its explanation. *J Dermatol Sci*. 2003 Aug;32(2):166-7. PubMed PMID: 12850310.

167: Ehsani A, **Namazi MR**, Barikbin B, Nazemi MJ. Unilaterally generalized keratosis pilaris. *J Eur Acad Dermatol Venereol*. 2003 May;17(3):361-2. PubMed PMID: 12702093.

168: Mirshams-Shahshahani M, **Namazi MR**. Xeroderma pigmentosum with limited involvement of the UV-exposed areas: a case report. *Int J Dermatol*. 2003 Apr;42(4):295-6. PubMed PMID: 12694497.

169: **Namazi MR**. Hypothesis: how could acne confer protection against malignant hematological disease. *J Dermatol Sci*. 2003 Apr;31(2):165. PubMed PMID: 12670728.

170: **Namazi MR**. A complementary note on the Morhenn's hypothesis on the pathomechanism of psoriasis. *Immunol Lett*. 2003 Feb 3;85(3):223. PubMed PMID: 12663134.

171: Feizy V, **Namazi MR**, Barikbin B, Ehsani A. Methotrexate-induced acral erythema with bullous reaction. *Dermatol Online J*. 2003 Feb;9(1):14. PubMed PMID:12639472.

172: **Namazi MR**. Nicotinamide-containing sunscreens for use in Australasian countries and cancer-provoking conditions. *Med Hypotheses*. 2003 Apr;60(4):544-5. PubMed PMID: 12615518.

173: **Namazi MR**. The potential efficacy of thalidomide in the treatment of recalcitrant

alopecia areata. Med Hypotheses. 2003 Apr;60(4):513-4. PubMed PMID:12615511.

174: **Namazi MR**. Minor thalassemia may be a risk factor for impulsiveness. Med Hypotheses. 2003 Mar;60(3):335-6. PubMed PMID: 12581607.

175: Mortazavi H, Ehsani A, **Namazi MR**, Hosseini M. Langerhans' cell histiocytosis. Dermatol Online J. 2002 Oct;8(2):18. PubMed PMID: 12546773.

176: **Namazi MR**, Barikbin B. Atypical crusted scabies in an Iranian man. Dermatol Online J. 2002 Oct;8(2):17. PubMed PMID: 12546772.

177: **Namazi MR**. Minor thalassemia as a protective factor against cerebrovascular accidents. Med Hypotheses. 2002 Sep;59(3):361-2. PubMed PMID: 12208171.

178: **Namazi MR**. Avicenna, 980-1037. Am J Psychiatry. 2001 Nov;158(11):1796. PubMed PMID: 11691684.

179: **Namazi MR**. Levamisole: a safe and economical weapon against pediculosis. Int J Dermatol. 2001 Apr;40(4):292-4. PubMed PMID: 11454092.

180: **Namazi MR**. Presentation of migraine as odontalgia. Headache. 2001 Apr;41(4):420-1. PubMed PMID: 11318893.